Nikon CeLL innovation Co. Ltd.(NCLi) announced an exclusive collaboration in 2015 with Lonza, a leader in pharmaceutical and biotech contract manufacturing, in order to establish a strong footprint in the Japanese regenerative medicine market. NCLi is well positioned to lead the Japanese regenerative medicine industry in development, manufacturing and testing services for cell and gene therapies. Lonza’s decades of experience in the cell and gene therapy industry and the best-in-class current Good Manufacturing Practice (cGMP) compliant facilities, operational, and quality systems are the basis for NCLi’s facility and systems. NCLi offers a broad selection of contract development and manufacturing services for early- to late-phase clinical and commercial cell and gene therapy products. NCLi will leverage Nikon’s core technologies in optics and image analysis and experience in precision manufacturing to bring high quality cell manufacturing technologies and Lonza’s technical know-how to the Japanese Market.
By entering into a new regenerative medicine contract manufacturing business, Nikon will actively be contributing to the early realization of Japan’s regenerative medicine, and will expand its business domain into adjacent technology areas. Furthermore, Nikon will prepare for the major breakthrough in the regenerative medicine market driven by iPSCs (induced Pluripotent Stem Cells), and will also be developing equipment and disposables needed to optimize the manufacture of high-quality cells and to provide clinical solutions, including both hardware and software from Japan, to the international market. NCLi’s primary mission is the prompt establishment of a reliable contract development and manufacturing infrastructure for cell and gene therapies.